Related Experiment Video
Updated: Mar 29, 2026
Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
Published on: January 7, 2022
The therapeutic potential of microbial proteasome inhibitors
1Institute of Microbial Chemistry (BIKAKEN), Numazu, 18-24 Miyamoto, Numazu-shi, Shizuoka 410-0301, Japan.
Abstract:
The proteasome influences cellular homeostasis through the degradation of regulatory proteins, many of which are also involved in disease pathogenesis. In particular, numerous regulatory proteins associated with tumor growth, such as cyclins, cyclin-dependent kinase inhibitors, tumor suppressors, and NF-κB inhibitors are degraded by the proteasome. Proteasome inhibitors can stabilize these regulatory proteins, resulting in the suppression of tumor development and the regulation of immune responses. Thus, proteasome inhibitors are promising candidate antitumor agents and immune-regulatory agents. Bortezomib is the first-in-class proteasome inhibitor approved for the treatment of multiple myeloma. Despite its high efficiency, however, a large proportion of patients do not attain sufficient clinical response due to toxicity and drug resistance. Therefore, the development of new proteasome inhibitors with improved pharmacological properties is needed. Natural products produced by microorganisms are a promising source of such compounds. This review provides an overview of proteasome inhibitors produced by microorganisms, with special focus on inhibitors isolated from actinomycetes.
Insights
Proteasome inhibitors target proteins crucial for cell health and disease, offering potential cancer treatments. New microbial compounds, particularly from actinomycetes, are being explored to overcome limitations of existing drugs like bortezomib.
Area of Science:
- Molecular Biology
- Biochemistry
- Pharmacology
Background:
- The proteasome regulates cellular homeostasis by degrading key proteins, including those implicated in tumor growth and immune responses.
- Proteasome inhibitors stabilize these regulatory proteins, showing promise as antitumor and immune-modulating agents.
- Bortezomib, a leading proteasome inhibitor, faces challenges with patient response due to toxicity and drug resistance.
Purpose of the Study:
- To review proteasome inhibitors derived from microorganisms.
- To highlight inhibitors isolated specifically from actinomycetes.
- To identify novel compounds with improved pharmacological properties for cancer therapy.
Main Methods:
- Literature review of microbial proteasome inhibitors.
- Focus on compounds isolated from actinomycetes.
- Analysis of pharmacological properties and therapeutic potential.
Main Results:
- Microorganisms are a rich source of proteasome inhibitors.
- Actinomycetes yield promising compounds with antitumor and immune-regulatory activities.
- These natural products offer potential alternatives to existing therapies.
Conclusions:
- Microbial proteasome inhibitors, especially from actinomycetes, represent a promising avenue for developing new cancer treatments.
- Further research into these natural products could lead to agents with enhanced efficacy and reduced toxicity compared to current drugs.
- The exploration of microbial natural products is crucial for addressing drug resistance and improving patient outcomes in oncology.
Related Concept Videos
01:29Microorganisms in Medicine and Therapeutics
01:13The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
01:23Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
01:28Biological Methods for Microbial Control
01:25Inhibitors of Bacterial Protein Synthesis